Yeah the valuation...
In 12 months, ANP would be well into the 'pivotal' open label study...concurrently in US and Europe....hopefully with one or two Big Pharma gorillas as partners.
With ODD on hand for both markets and 7 to 10 years of exclusivity....the DMD $6B market alone will get us a valuation well north of $1.50 imo.
I agree with Sammy, lets list on NASDAQ.
Research report, page-15
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |